Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
AstraZeneca’s cediranib may not have made the cut as a single agent to treat ovarian cancer, but Yale researchers think it could serve as a powerful add-on to amplify the effects of PARP inhibitors.
The theory has been that cediranib works by blocking the formation of new blood vessels, thus depriving tumors of the nutrition and oxygen necessary to live and grow. But in a mouse trial, a team out of Peter Glazer’s lab found that the drug also directly affects pathways involved in DNA repair — a potentially more useful function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.